Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

CAR T-cell therapy can be used to send multiple myeloma into lasting remission

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 05.06.17
Views: 1262
Rating:

Dr Wanhong Zhao - Xi’an Jiaotong University Hospital, China

Dr Zhao presents, at a press conference at ASCO 2017, findings from an early clinical trial looking at a new type of immunotherapy ̶ chimeric antigen receptor (CAR) T cells targeting B-cell maturation protein or BCMA. 

33 out of 35 (94%) patients had clinical remission of multiple myeloma upon receiving CAR T-cell therapy. 

Read the news story for more. 

 

Related videos

follow us

ONJ e-learning


Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation